Please login to the form below

Not currently logged in
Email:
Password:

Two MDs leave CCC

Carsten Edwards, MD of Brandtectonics Access, and Vicky Hunt, MD of Allidura, are leaving Chandler Chicco Companies

Carsten Edwards, MD of Brandtectonics Access, and Vicky Hunt, MD of Allidura, are leaving Chandler Chicco Companies (CCC).

It is believed that Edwards will be moving to Ogilvy Healthworld at the end his three-month notice period. He joined CCC in 2008, first as director at Brandtectonics, and he was promoted to MD in April 2010. Prior to this, Edwards was at Bristol-Myers Squibb.

Vicky Hunt is leaving CCC after 10 years to move out of London and spend more time with her family. While at CCC she worked in three of its business units, leading two of them for periods.

Fiona Hall, EU MD at CCC said: "We are very sad to see Vicky leave but wish her the very best and hope she really enjoys spending more time with her children. We also thank Carsten and wish him well for the future."

A new MD for Allidura will be "announced in due course." It is unclear whether Edwards would be replaced.

Brandtectonics Access underwent a restructure in December 2010 when it was split across a number of CCC businesses following an annual review.

Hall said: "We review our business on an annual basis to consider how we can evolve to best service the needs of our clients moving forward. It became clear to us that our clients' growing market access needs would be best served by integrating our offer across the CCC business units so that market access counsel would be readily available and integrated."

CCC has said it will be looking at how to move Brandtectonics forward in light of these recent changes.

12th April 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

Virtual meeting technologies for reducing emissions and waste in the healthcare industry
...
Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...